Clinical Trial Update: Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating efficacy and safety of apremilast in children aged 6 to 17 with moderate to severe plaque psoriasis is completed. Results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• OTEZLA (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2023-12-07